Raltitrexed

Raltitrexed

SCHEMBL16583752

Cc1nc2ccc(CN(C)c3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)s3)cc2c(=O)[nH]1.O

nearest known ligand 0.98

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

TYMS

The experimentally established mechanism targets of Raltitrexed. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
TYMS known ✓ P04818 9/20 0.98
DHFR P00374 1/20 0.98
FOLR2 P14207 1/20 0.98
FOLR1 P15328 1/20 0.98
SLC19A1 P41440 1/20 0.98
EHMT2 Q96KQ7 1/20 0.98
SLC46A1 Q96NT5 1/20 0.98

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Raltitrexed SCHEMBL28154699 1.00 TYMS (0.98) TYMSDHFRFOLR2FOLR1SLC19A1
Raltitrexed SCHEMBL28155448 1.00 TYMS (0.98) TYMSDHFRFOLR2FOLR1SLC19A1
Raltitrexed SCHEMBL28369835 0.99 TYMS (0.97) TYMSDHFRFOLR2FOLR1SLC19A1
Raltitrexed SCHEMBL29490413 0.99 TYMS (1.00) TYMSDHFRFOLR2FOLR1SLC19A1
Raltitrexed SCHEMBL7438 0.99 TYMS (1.00) TYMSDHFRFOLR2FOLR1SLC19A1
Raltitrexed SCHEMBL13959 0.99 TYMS (1.00) TYMSDHFRFOLR2FOLR1SLC19A1
Raltitrexed SCHEMBL6240639 0.99 TYMS (1.00) TYMSDHFRFOLR2FOLR1SLC19A1
Raltitrexed SCHEMBL12078376 0.99 TYMS (1.00) TYMSDHFRFOLR2FOLR1SLC19A1
Raltitrexed SCHEMBL21248507 0.98 TYMS (0.98) TYMSDHFRFOLR2FOLR1SLC19A1
Raltitrexed SCHEMBL28384446 0.98 TYMS (0.98) TYMSDHFRFOLR2FOLR1SLC19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150087605-A1 Compositions and Methods Comprising Carboxylic Acid-Containing Small Molecules UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. 2015-03-26 US claimed
CN-106957312-B Raltitrexed hydrate crystal forms and preparation method thereof NANJING CHIA TAI TIANQING PHARMACEUTICAL CO., LTD. (CN) 2019-11-01 CN disclosed
CN-106957311-A Solvate of Raltitrexed and preparation method thereof 南京正大天晴制药有限公司 2017-07-18 CN disclosed
CN-106957311-A Solvate of Raltitrexed and preparation method thereof 南京正大天晴制药有限公司 2017-07-18 CN disclosed
CN-106957312-A Raltitrexed hydrate crystal forms and preparation method thereof 南京正大天晴制药有限公司 2017-07-18 CN disclosed
US-20150087605-A1 Compositions and Methods Comprising Carboxylic Acid-Containing Small Molecules UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. 2015-03-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150087605-A1 Compositions and Methods Comprising Carboxylic Acid-Containing Small Molecules ANTXR2, AADAC, HAAO TYMS 3475/4885DHFR 1134/4885FOLR2 2879/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.